MacroGenics Inc (MGNX) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.98
• Market Cap: $121.46M
• EPS: $-1.34
• 52-Week High: $2.50
• 52-Week Low: $0.99

Market Sentiment

MacroGenics Inc currently has a Bearish sentiment score of -0.49.

About MacroGenics Inc

MacroGenics, Inc. is a clinical-stage biopharmaceutical company based in Rockville, Maryland, focused on developing cutting-edge antibody-based therapies for cancer treatment. Utilizing proprietary technology platforms, MacroGenics seeks to address critical unmet medical needs in oncology through a robust pipeline of differentiated drug candidates. By establishing strategic partnerships and advancing its clinical programs, the company is poised to enhance treatment options and patient outcome...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for MacroGenics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does MGNX pay dividends?

MacroGenics Inc (MGNX) does not currently pay a regular dividend.

What is MGNX's market cap?

MacroGenics Inc (MGNX) has a market capitalization of $121.46M with a current stock price of $1.98.